BR112019003987A2 - formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc - Google Patents

formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc

Info

Publication number
BR112019003987A2
BR112019003987A2 BR112019003987A BR112019003987A BR112019003987A2 BR 112019003987 A2 BR112019003987 A2 BR 112019003987A2 BR 112019003987 A BR112019003987 A BR 112019003987A BR 112019003987 A BR112019003987 A BR 112019003987A BR 112019003987 A2 BR112019003987 A2 BR 112019003987A2
Authority
BR
Brazil
Prior art keywords
solid forms
cenicriviroc mesylate
mesylate solid
production processes
cenicriviroc
Prior art date
Application number
BR112019003987A
Other languages
English (en)
Portuguese (pt)
Inventor
Kay Sharp Emma
Ian Cooper Martin
Phiasivongsa Pasit
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of BR112019003987A2 publication Critical patent/BR112019003987A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019003987A 2016-08-31 2017-08-30 formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc BR112019003987A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
BR112019003987A2 true BR112019003987A2 (pt) 2019-05-28

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003987A BR112019003987A2 (pt) 2016-08-31 2017-08-30 formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc

Country Status (13)

Country Link
US (1) US10301287B2 (https=)
EP (1) EP3506896A4 (https=)
JP (2) JP2019526628A (https=)
KR (1) KR20190057066A (https=)
CN (1) CN110167550A (https=)
AU (1) AU2017321594A1 (https=)
BR (1) BR112019003987A2 (https=)
CA (1) CA3034606A1 (https=)
MX (1) MX2019002057A (https=)
RU (1) RU2019109019A (https=)
SG (1) SG11201901438VA (https=)
TW (1) TW201823235A (https=)
WO (1) WO2018045043A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11613670B2 (en) 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11298876B2 (en) 2018-06-19 2022-04-12 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
KR20210053921A (ko) * 2018-08-31 2021-05-12 에보니크 오퍼레이션즈 게엠베하 중합체 분말을 제조하는 방법
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US12466817B2 (en) 2020-05-22 2025-11-11 Nicoya Therapeutics (Shanghai) Co., Ltd Pyridine derivative and application thereof
US20240124690A1 (en) * 2021-02-22 2024-04-18 Asahi Kasei Kabushiki Kaisha Composition Containing Cellulose Nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CA2191980A1 (en) 1994-07-04 1996-01-18 Takashi Sohda Phosphonic acid compounds, their production and use
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
PE20030329A1 (es) 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
WO2005089714A1 (ja) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CN103402998B (zh) 2010-11-18 2017-09-26 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
JP2015520144A (ja) 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトAkron Molecules Ag 疼痛の治療のための化合物の使用
CN105263498B (zh) 2013-05-15 2019-04-26 妥必徕疗治公司 赛尼克韦罗组合物及其制备和使用方法
HK1232147A1 (zh) 2014-03-21 2018-01-05 Tobira Therapeutics, Inc. 用於治疗纤维化的赛尼克韦罗
US20170105969A1 (en) * 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス, インコーポレイテッド セニクリビロックの製造方法及び関連類似体

Also Published As

Publication number Publication date
EP3506896A4 (en) 2020-08-26
EP3506896A1 (en) 2019-07-10
CA3034606A1 (en) 2018-03-08
WO2018045043A1 (en) 2018-03-08
TW201823235A (zh) 2018-07-01
CN110167550A (zh) 2019-08-23
RU2019109019A3 (https=) 2021-08-23
KR20190057066A (ko) 2019-05-27
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21
SG11201901438VA (en) 2019-03-28
MX2019002057A (es) 2019-11-18
US20180057481A1 (en) 2018-03-01
US10301287B2 (en) 2019-05-28
RU2019109019A (ru) 2020-10-01
AU2017321594A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
BR112019003987A2 (pt) formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc
MX2018014154A (es) Polinucleotidos moduladores.
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
IL259023A (en) Compositions containing protein loaded exosomes and methods for preparing same and uses thereof
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
MX2019003406A (es) Estructuras de nonofibra y metodos de uso de las mismas.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX388350B (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
MX376083B (es) Formas de dosificacion solidas de palbociclib.
PT3317260T (pt) Composições de acessulfame de potássio e processos de produção das mesmas
HUE072609T2 (hu) Fenfluramin-készítmények és elõállítási eljárásaik
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
PT3393485T (pt) Composições probióticas e uso das mesmas
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
EA201791716A1 (ru) Фармацевтический состав
MX2017000862A (es) Formulacion de factor viii.
BR112018006560A2 (pt) composições para higiene bucal e métodos de uso das composições.
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
MX2017007596A (es) Procedimiento para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina; y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements